Cooley advised Abaxis on its sale to Zoetis, a leading animal health company, for $83 per share in cash or approximately $2 billion in aggregate.
Cooley advised Abaxis on its sale to Zoetis, a leading animal health company, for $83 per share in cash or approximately $2 billion in aggregate.